Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

2.

Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial.

Hopkins WJ, Elkahwaji J, Beierle LM, Leverson GE, Uehling DT.

J Urol. 2007 Apr;177(4):1349-53; quiz 1591.

PMID:
17382730
3.

Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections.

Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Leverson GE.

J Urol. 2003 Sep;170(3):867-9.

PMID:
12913718
4.

Vaginal mucosal immunization for recurrent urinary tract infection: phase II clinical trial.

Uehling DT, Hopkins WJ, Balish E, Xing Y, Heisey DM.

J Urol. 1997 Jun;157(6):2049-52.

PMID:
9146577
5.

Vaginal mucosal immunization for recurrent urinary tract infection: extended phase II clinical trial.

Uehling DT, Hopkins WJ, Beierle LM, Kryger JV, Heisey DM.

J Infect Dis. 2001 Mar 1;183 Suppl 1:S81-3. No abstract available.

PMID:
11171022
6.

Phase I clinical trial of vaginal mucosal immunization for recurrent urinary tract infection.

Uehling DT, Hopkins WJ, Dahmer LA, Balish E.

J Urol. 1994 Dec;152(6 Pt 2):2308-11.

PMID:
7966729
7.

Vaginal immunization of monkeys against urinary tract infection with a multi-strain vaccine.

Uehling DT, Hopkins WJ, James LJ, Balish E.

J Urol. 1994 Jan;151(1):214-6.

PMID:
8254817
8.

Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis.

Naber KG, Cho YH, Matsumoto T, Schaeffer AJ.

Int J Antimicrob Agents. 2009 Feb;33(2):111-9. doi: 10.1016/j.ijantimicag.2008.08.011. Review.

PMID:
18963856
9.

Two subtypes of hepatitis B virus-associated glomerulonephritis are associated with different HLA-DR2 alleles in Koreans.

Park MH, Song EY, Ahn C, Oh KH, Yang J, Kang SJ, Lee HS.

Tissue Antigens. 2003 Dec;62(6):505-11.

PMID:
14617034
10.

Human leukocyte antigens in women with recurrent urinary tract infections.

Schaeffer AJ, Radvany RM, Chmiel JS.

J Infect Dis. 1983 Sep;148(3):604.

PMID:
6604762
11.
12.

Recurrent urinary tract infection in women.

Hooton TM.

Int J Antimicrob Agents. 2001 Apr;17(4):259-68. Review.

PMID:
11295405
13.
14.

Abnormal immunological profile and vaginal microbiota in women prone to urinary tract infections.

Kirjavainen PV, Pautler S, Baroja ML, Anukam K, Crowley K, Carter K, Reid G.

Clin Vaccine Immunol. 2009 Jan;16(1):29-36. doi: 10.1128/CVI.00323-08.

15.
16.

Vaccine-induced protection against gastrointestinal bacterial infections in the absence of secretory antibodies.

Uren TK, Wijburg OL, Simmons C, Johansen FE, Brandtzaeg P, Strugnell RA.

Eur J Immunol. 2005 Jan;35(1):180-8.

17.

The effects of vaccination with inactivated uropathogenic bacteria in recurrent urinary tract infections of children.

Nayir A, Emre S, Sirin A, Bulut A, Alpay H, Tanman F.

Vaccine. 1995 Aug;13(11):987-90.

PMID:
8525693
18.

Hepatitis B vaccine nonresponse and celiac disease.

Noh KW, Poland GA, Murray JA.

Am J Gastroenterol. 2003 Oct;98(10):2289-92.

PMID:
14572581
19.

Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle.

Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, Cu-Uvin S, Neutra MR.

J Immunol. 2002 Jul 1;169(1):566-74.

20.

Pathogenesis of urinary tract infections: an update.

Hooton TM.

J Antimicrob Chemother. 2000 Sep;46 Suppl 1:1-7; discussion 63-5. Review.

PMID:
11051617
Items per page

Supplemental Content

Support Center